Skip to content

SuPr Study (Supine Versus Prone Treatment Position in Breast Radiotherapy)

A Randomised Trial Investigating the Prone Treatment Position as a Method of Sparing Healthy Tissues in Women Prescribed Breast Radiotherapy (SuPr Study)

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01001728
Acronym
SuPr
Enrollment
25
Registered
2009-10-27
Start date
2008-11-30
Completion date
2009-11-30
Last updated
2016-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Breast Cancer, Radiotherapy, Prone position

Brief summary

A randomised, two-arm, non-blinded crossover study investigating the impact of treatment position (prone versus supine) upon reproducibility of tumour bed position in patients undergoing breast radiotherapy following excision of early breast cancer.

Detailed description

To establish whether or not the prone (face down) position reduces exposure of healthy tissue to radiation when compared to the supine position. To compare patient comfort and acceptability in each of the prone and supine positions. To perform a time and motion study for radiotherapy planned and delivered in each of the prone and supine positions.

Interventions

RADIATIONImaging investigations (with radiation)

Sponsors

Royal Marsden NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Complete microscopic excision of early stage invasive ductal or lobular carcinoma (pT1-3b N0-1 M0) with breast preservation. * Paired titanium clips marking anterior, posterior, and radial walls of excision cavity * Breast cup size C or above * Recommendation for whole breast radiotherapy * No requirement for nodal irradiation * Ability to lie prone on breast board * For left-sided breast cancer patients, cardiac and LAD doses must be ≤10% greater than those predicted for the supine position. * For all patients, the following absolute dose constraints should be met: ≤5% of heart volume to receive 18Gy and ≤10% of ipsilateral lung volume to receive ≥20Gy * Age ≥18 * PS ≤1 * No previous radiotherapy to the affected breast * No concomitant herceptin * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. * Written informed consent given according to ICH/GCP before registration/ randomisation. * Patients can only be randomised into this trial once.

Design outcomes

Primary

MeasureTime frame
Interfraction reproducibility of tumour bed position (Reproducibility of tumour bed position in supine versus prone positions compared using the difference in mean daily displacement in tumour bed centre of gravity over a course of radiotherapy in 3D).End of radiotherapy

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026